Ironwood Pharmaceuticals (IRWD) Cash & Current Investments (2010 - 2026)

Ironwood Pharmaceuticals has reported Cash & Current Investments for 17 years, with the latest figure at $220.5 million in Q1 2026.

• Quarterly Cash & Current Investments rose 103.23% year-over-year to $220.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $220.5 million (up 103.23% YoY) and the FY2025 annual result came in at $215.5 million, up 143.29% from the prior year.
• Cash & Current Investments rose to $220.5 million in Q1 2026 per IRWD's latest filing, from $215.5 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $741.6 million in Q1 2023 and troughed at $88.2 million in Q3 2024.
• A 5-year average of $272.7 million and a median of $140.4 million in 2025 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments sank 85.98% in 2023, then soared 143.29% in 2025.
• Over 5 years, Cash & Current Investments stood at $657.5 million in 2022, then plunged by 85.98% to $92.2 million in 2023, then slipped by 3.9% to $88.6 million in 2024, then jumped by 143.29% to $215.5 million in 2025, then climbed by 2.33% to $220.5 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $220.5 million, $215.5 million, and $140.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.